Cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

Abstract: A new human/human fused cell clone derived from human B cells having the ability to produce immuno­ globulins and human B cells substantially lacking the ability to produce immunoglobulins, antigen-specific human immunoglobulins produced by the human/human fused cell clone, and a method of producing the human immuno­ globulins. More specifically, a human/human hybridoma having the ability to produce antigen-specific human immunoglobulins, which is a human/human fused cell strain derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain; and antigen-specific human immunoglobulins produced by the human/human fused cell strain.

Description: This invention relates to two new human/human fused cell clones derived from human B cells having the ability to produce immunoglobulins and human B cells substantially lacking the ability to produce immunoglobulins, to antigen-specific human immunoglobulins produced by the human/human fused cell clones, and to a method of producing the human immunoglobulins. More specifically, this invention relates to two human/human hybridomas having the ability to produce antigen-specific human immunoglobulins, which hybridomas are human/human fused cell strains derived from human B cells of a human patient with liver cancer and a subclone of a human lymphoblast cell strain. The invention also relates to antigen-specific human immunoglobulins produced by the human/human fused cell strain. The antigen-specific human immunoglobulins are useful in medical, pharmaceutical and biochemical fields, for example for prevention, treatment and diagnosis of human liver cancer, the preparation of biochemical reagents and biopolymers, and purification of cancer antigens. It has previously been reported that mouse B cells sensitized with cancer or other antigens and mouse B cells from a mouse with myeloma were fused outside the mouse's body to produce mouse/mouse fused cells having the ability to produce mouse immunoglobulins specific for the above antigens and self-replicability [for example, "Koehler G. and Milstein C.: Nature, 256, 495 (1975) and Dippold, E.G., Lloyd, K.O., Li, L. T. C., Ikeda, H., Oettgen, H. F. and Old, L. J.: Proc. Nat. Acad. Sci., U. S. A. 77, 6114 (1980)]. It was also reported that human B-cells sensitized with an antigen and mouse B cells from a mouse with myeloma were fused outside the body to produce human/mouse fused cells having the ability to produce human immunoglobulins specific to the antigen and self-replicability [for example, Schlom, J., Wenderrich, P., and Teramoto, Y. A.: Proc. Nat. Acad. Sci., U. S. A., 77 (11), 6841 (1984)]. However, in the latter attempt to obtain fused cells having the ability to produce immunoglobulins, loss of chromosomes occurs with time, and the ability of the fused cells to produce human immunoglobulins is lost with time. Thus, the fused cells obtained by the latter attempt have the serious defect that their ability to produce immunoglobulins is very unstable. As an attempt to form human/human fused cells having the ability to produce human immunoglobulins, it was reported that human B cells sensitized with measles virus or hapten (2,4-dinitrophenyl) were used as a donor and fused outside the body with a cell line (human B cell, parent cell line) having the ability to produce human immunoglobulins taken from a patient with myeloma to produce human/human cells having the ability to produce human immunoglobulins specific to the above antigen and self-replicability [for example, Croce, C. M., Linnenbach, A., Hall, W., Steplowski, Z., and Koprowski, H.: Nature, 288, 488 (1980), and Olsson, L. and Kaplan, H. S.: Proc. Nat. Acad. Sci., U. S. A., 7 (9), 5429 (1980]. The mouse/mouse hydbridoma obtained by the above method can produce only mouse immunoglobulins. When the mouse/human hybridoma is cultivated, the formation of products derived from the mice inevitably form in the culture, and with loss of human chromosomes, the hybridoma may lose the ability to produce human immunoglobulins. For this reason, it is desired to produce human immunoglobulins from the human/human fused cells. The above-cited papers reporting human immunoglobulins produced from the human/human hybridoma do not show any proof of the bindability of the immunoglobulins to cancer cells. In particular, these papers fail to describe anything on the bindability of the immunoglobulins to liver cancer cells and liver cancer tissues. One of the inventors of the present application created a human/human hybridoma which is a human/human fused cell derived from human B cell taken from a human patient with cervical cancer of the uterus and a subclone of a human lymphoblast cell strain and which has the ability to produce antigen-specific human immunoglobulin (Japanese Laid-Open Patent Publication No. 137497/1984). This patent document discloses that the human immuloglobulin produced by the hybridoma showed a stronger power of binding to cervical epitheloid carcinoma cells and cell lines Hela and Caski derived from the above cells than to normal fibroblast cells (W1-38). It, however, fails to refer to its bindability to human liver cancer cells and human liver cancer tissues. Japanese Laid-Open Patent Publication No. 44900/1986 (European Laid-Open Patent Publication No. 171083) describes a monoclonal antibody which specifically reacts with antigens related to pancreas cancer, colon cancer and liver cancer, and states that fused cells for producing the monoclonal antibody are obtained by fusion of antibody-producing cells with bone marrow cells which are preferably derived from animals of the same species. This patent document specifically discloses only a mouse/mouse fused cell strain. Japanese Laid-Open Patent Publications Nos. 167699/1986 and 36398/1987 give statements on monoclonal antibodies which specifically react with esophagus cancer, lung cancer, stomach cancer and liver cancer, and fused cells capable of producing the monoclonal antibodies are obtained by fusion of antibody-producing cells with myeloma cells. These patent documents specifically disclose only mouse/mouse fused cell lines. The patent documents only show the bindability of the monoclonal antibodies produced by mouse/mouse fused cells to human liver cancer cells (HEK) as a specific example of bindability to liver cancer cells. They fail to refer to bindability to other liver cancer cells or human liver cancer tissues. They show nothing on monoclonal antibodies produced by human/human hybridomas and their bindability to liver cancer cells or tissues. The present inventors have succeeded in creating two human/human hybridomas which are human/human fused cells derived from human B cells of a human patient with liver cancer and subclones of human lymphoblast cells, and which have the ability to produce antigen-specific human immunoglobulins. One of the human/human hybridomas (TOH/B9, FERM BP-1883) has the immunological characteristics of the human B cells of the human liver cancer patient and continues to have these characteristics stably. Further, this hybridoma has the ability to produce antigen-specific human immunoglobulin A (IgA) monoclonal antibody which binds to human liver cancer cells. Accordingly, the invention provides human/human hybridoma TOH/B9 (FERM BP-1883) which produces antigen-specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. The other human/human hybridoma of the invention (TOH/D5, FERM BP-1882) also has the immunological characteristics of the human B cells from the human liver cancer patient and continues to have these characteristics stably. This hybridoma has the ability to produce antigen-specific human immunoglobulin G (IgG) monoclonal antibody which binds to human liver cancer cells and human liver cancer tissue (e.g. a slice of human liver cancer tissue obtained by fixing it with formalin and then embedding it in paraffin). Accordingly, the invention provides human/human hybridoma TOH/D5 (FERM-BP 1882) which produces antigen specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. The inventors successfully produced antigen specific human immunoglobulin from hybridomas TOH/B9 and TOH/D5. Accordingly, the invention includes an antigen-specific human immunoglobulin which is obtainable from human/human hybridoma TOH/B9 (FERM BP-1883) and which has the following biochemical properties: (a) it is a human immunoglobulin A (IgA), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) derived from human liver cancer. The invention also includes an antigen-specific human immunoglobulin which is obtainable from human/human hybridoma TOH/D5 (FERM BP-1882) and which has the following biochemical properties: (a) it is human immunoglobulin G (IgG), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue. The immunoglobulins of the invention can be produced from the hybridomas of the invention by a method which comprises culturing a hybridoma of the invention in a culture medium, and recovering the immunoglobulin from the culture broth. The hybridomas of the invention can be produced by a method which comprises culturing a human B cell taken from a human patient with liver cancer in the presence of a human B cell growth factor and an anti-human IgM antibody, and fusing the B cell with a subclone of a human lymphoblast cell strain. The human/human hybridomas of this invention are human/human fused cells derived from human B cells which can be obtained from, for example, the blood, lymph nodes, spleen or bone marrow of a human patient with liver cancer and a subclone (human B cells) of human lymphoblast cells, for example HIH/TOl (FERM BP-1884). The present inventors have, for the first time, produced human/human hybridomas having the ability to produce human immunoglobulins binding specifically to liver cancer-related antigens by fusing human B cells of a patient with liver cancer with a subclone (human B cells) of lymphoblast cells substantially lacking the ability to produce immunoglobulins. Prior to the fusion operation, the human B cells of the liver cancer patient are subjected to a preliminary cultivation treatment in the presence of a human B cell growth factor (e.g. human BCGF) and an anti-human IgM antibody (e.g. anti-µ). The preliminary cultivation treatment may, for example, be carried out by utilizing a suitable basal medium containing human BCGF and anti-µ or a modified form of this medium in an atmosphere containing 5 % CO₂ at a temperature of about 30 °C ±3 °C for about 5 to 7 days. Known basal media or modified media exemplified, for example, in Japanese Laid-Open Patent Publication No. 51983/1987 may be used as the basal or modified medium. The culture media may contain other known growth factors, amino acids, vitamins, minerals, sugars, coenzymes and fatty acids, for example. Human BCGF and anti-µ are commercially available, and methods for their preparation are known. For the former, see, for example, Abbby Maizel et al., Proc. Natl. Acad. Sci., U. S. A., vol. 79, 5998-6002 (1982), and for the latter, see, for example, "Immunochemistry" (Japanese-language publication), edited by Shunsuke Uda, pages 51-63, published by Nakayama Shoten, 1972). The amounts of these materials may be easily selected experimentally. For example, based on the volume of the medium, about 5 to 20 % by volume of human BCGF and about 5 to 100 micrograms/ml-medium of anti-µ may be used. In the present invention, the fused cells may be produced, for example, by contacting the human B cells of the human liver cancer patient with the subclone of human lymphoblast cells in a solvent by using a fusion promotor such as Sendai virus (HVJ) or polyethylene glycol or by using an electrofusion apparatus. For example, the above human B cells and the subclone are placed in an aqueous medium in the presence of the fusion promotor, and the system is made homogenous by optionally stirring it gently. The homogenous system is allowed to stand for a time sufficient to produce a fused cell from one human B cell and one subclone (human B cell), for example for several minutes, to give the desired fused cells. The solvent may be, for example, water, physiological saline, a 5 % aqueous solution of dimethyl sulfoxide, or a 5 % aqueous solution of glycerol. The broth in which the desired fused cells have been produced is, for example, centrifuged and the cells are harvested. They are dispersed in a suitable medium such as a medium obtained by adding HATO reagent to a RPMI-1640 liquid medium containing 10 % calf or bovine fetal serum. The dispersion is dividedly injected into the wells of a microtiter plate at a fixed rate, and cultivated, for example, at 37 °C in the presence of 5 % CO₂. A medium (RDF) composed of a mixture of RPMI-1640, DME and F-12 (2:1:1) may be used instead of the RPMI-1640 medium mentioned above. The culture fluid in each well is replaced by a fresh one every three days, and the cultivation is continued, for example, for 2 weeks. The formation of fused cells is examined under a microscope. The culture fluids of the wells in which the formation of a fused cell colony is observed are taken. The presence of human immunoglobulin in the culture fluids can be detected by, for example, radioimmunoassay using ¹²⁵ I, or an enzyme-labelled antibody technique. The colonies in which the production of human immunoglobulins is observed are transferred to a fresh medium, and cultivated. As a result, the fused cells proliferate, and fused cell clones can be obtained. As required, by sub-cloning, clones having the ability to produce human immunoglobulins binding specifically to cancer-related antigens such as human liver cancer can be obtained. In the practice of this embodiment, the techniques described in Glassy, M. C., Handley, H. H., Hagiwara, H. and Royston, I.: Proc. Nat. Acad. Sci., U. S. A., 80 , 6327 (1983) and "Koso Kotai Ho" (Enzyme-Labelled Antibody Technique), edited by Keiichi Watanabe, Gakusai Kikaku, pages 33-118 (1956) may be used. For example, by biopsy, lymphoblasts are taken from the spleen of a healthy person, or lymphatic cells such as lymphocytes, from a patient with myeloma. B cell lymphocytes substantially having no ability to produce immunoglobulins are selected and separated. Thus, human B cells having such sensitivity that they are resistant to 6-thioguanine and ouabain and die in HATO medium can be obtained. For example, the human B cells, HIH/TOl, used in a working example given hereinafter can be obtained by cultivating the aforesaid lymphoblasts in a medium containing 6-thioguanine and ouabain as shown in Referential Example 1 given hereinafter. Samples of the hybridomas having the ability to produce antigen-specific immunoglobulins, TOH/B9 and TOH/D5, produced from human B cells of a human patient with liver cancer, and of the subclone HIH/TOl of human lymphoblast cells have been deposited in accordance with the Budapest Treaty with the Fermentation Research Institute of Japan under Accession Numbers FERM BP-1883, FERM BP-1882 and FERM BP-1884, respectively. The cytobiochemical properties of the hydridomas are described below. Human/human hybridoma TOH/B9 (1) Human immunoglobulin A (IgA) secreting (producing) (2) Doubling time: about 37 hours (3) The DNA content is about 2 times, for example 1.5 to 2.5 times, that of normal human lymphocytes. (4) IgA in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) (liver cancer). (5) It can be divided and proliferated in HATO medium (medium containing hypoxanthine, amethopterin, thymidine and ouabain). Human/human hybridoma TOH/D5 (1) Human immunoglobulin G (IgG) secreting (producing) (2) Doubling time: about 37 hours (3) The DNA content is about 2 times, for example 1.5 to 2.5 times, that of normal human lymphocytes. (4) IgG in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) or a formalin-fixed paraffin-embedded slice of human liver cancer tissues. (5) It can be divided and proliferated in HATO medium (medium containing hypoxanthine, amethopterin, thymidine and ouabain). The relative DNA content (the ratio to the DNA content of normal human lymphocytes) is determined by analysis with a flow cytometer after staining the sample with propidium iodide. The antigen-specific human immunoglobulins of this invention can be produced by cultivating fused cells derived from human B cells of a human liver cancer patient and a subclone (human B cells) of human lymphoblast cells which have the ability to produce antigen-specific human immunoglobulins, and recovering the antigen-specific human immunoglobulins from the culture broth. For example, the human/human hybridoma produced as described above is cultivated in a suitable medium such as RPMI-1640 medium containing 10 % bovine fetal serum, and a substance containing immunoglobulins binding specifically to a cancer-related antigen such as human liver cancer cells can be obtained from the culture broth. A serum-free medium may be used in the cultivation of the human/human hybridoma, and this is advantageous because it enables the resulting immunoglobulins to be purified easily. Such a serum-free medium is described, for example, in Japanese Laid-Open Patent Publication No. 51983/1987 (Japanese Patent Application No. 192145/1985) filed by the same applicants as the present applicants. If desired the above substance may be purified to form pure immunoglobulins. The purification may be carried out by purification means which can be used in purifying immunoglobulins taken from biological fluids, for example an ammonium sulfate method, affinity chromatography, gel filtration, ion-exchange chromatography and electrophoresis. In obtaining a substance containing immunoglobulins binding specifically to a cancer-related antigen such as human liver cancer cells or the immunoglobulins from the fusion cell clones or the culture thereof in accordance with this invention, it is advantageous to inoculate an antigenic tissue (such as a cancer tissue) in an animal lacking the ability, or having a very weak ability, to produce immunological substance, such as a nude mouse, maintaining the inoculated tissue, searching a human immunoglobulin (antibody) which reacts with the tissue so maintained or returned to the cultivation system, and to separate it. Other examples of the medium that can be utilized in cultivating the human/human hybridoma include RDF medium composed of a 2:1:1 mixture of RPMI-1640 medium containing 10 % bovine fetal serum, Dulbecco medium and HAM medium, and RDF medium containing transferin, insulin, sodium selenite, ethanolamine and beta-mercaptoethanol. The cultivation may be carried out in the presence of 5 % CO₂ at 37 °C. Examples of the cancer-related antigen-specific human immunoglobulin of the invention which can be obtained as above are immunogloblins obtained by using the aforesaid human/human hybridoma TOH/B9 and human/human hybridoma TOH/D5. Their characteristics are shown below. Cancer-related antigen-specific human immunoglobulin produced by human/human hybridoma TOH/B9 (a) It is human immunoglobulin A (IgA). (b) It has a power of binding to human cell line PLC/PRF/5 (Alexander cells) (liver cancer). (c) It contains a heavy chain having a molecular weight of about 60,000 and a light chain having a molecular weight of about 20,000. Cancer-related antigen-specific human immunoglobulin produced by human/human hybridoma TOH/D5 (a) It is human immunoglobulin G (IgG). (b) It shows bindability to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue. (c) It consists of H- and L-chains and has a molecular weight of about 150,000. The human cell line PLC/PRF/5 (Alexander cells) (liver cancer) is freely available from American Type Culture Collection as ATCC CR1, 8024. The antigen-specific human immunoglobulins of this invention can inhibit proliferation of human cancer cells such as human liver cancer cells or kill them by their own action or by the action of an antibody acting on human cancer cells such as human liver cancer cells. Alternatively, with the aid of complements or T-lymphocytes, they can inhibit proliferation of cancer cells or kill them. Furthermore, they are useful for inhibiting the proliferation, or kill, cancer cells when used in the form of a chemotherapeutic agent-bound human monoclonal antibody, an interferon-bound human monoclonal antibody, a high-molecular toxin-bound human monoclonal antibody, a drug-containing liposome-bound human monoclonal antibody using a cancer-specific antibody produced in great quantities outside the human body as a carrier. When a radioactive ray-sensitive substance is bound to the human monoclonal antibody obtained in this invention used as a carrier and administered to a patient with cancer, the monoclonal antibody gather selectively at the cancer cells. This enables detection of a diseased part and can be utilized in radiotherapy. In utilizing the immunoglobulins of the invention against cancer, only a completely monoclonal antibody may be used. It is also possible to create a more effective modified human monoclonal antibody by a chemical method by cutting the antibody into a smaller molecule containing a specific antigen recognizing site, or bonding such a smaller molecule or only the specific antigen recognizing site to a non-specific antigen recognizing site of another antibody, and use the modified human monoclonal antibody. The following examples illustrate the present invention in greater detail. REFERENTIAL EXAMPLE 1 Human B cell-lymphoblast cells HIH/TOl Human B cell-lymphoblast cells WI-L2 ["Journal of the National Cancer Institute", Vol. 46, No. 3, pp. 647-654 (1971)] were cultivated and adapted in a serum-free medium obtained by adding moderate amounts of insulin, transferin, selenium, ethanolamine, beta-mercaptoethanol and bovine serum albumin to a basal medium RDF. The culture broth was inoculated in a 96-well microtiter plate containing the serum-free medium at a rate of 1 cell/well, and sujected to a cloning operation by a limiting dilution method in the presence of 5 % CO₂ at 37 °C. After the lapse of about one month, one clone which did not substantially produce immunoglobulins IgG and IgM in the medium was selected from 50 wells where the above cells proliferated. This selected clone was cultivated and adapted in the same serum-free medium as above containing 0.1 µM 6-thioguanine. The cultivation was carried out at 37 °C in the presence of 5 % CO₂. Every time subcultivation was repeated, the concentration of 6-thioguanine was stepwise increased from 0.2 µM to 0.5, 1, 2, 4, 10, 15 and 20 µM. Finally, a monoclone replicable in a serum-free medium containing 20 µM of 6-thioguanine was selected by cloning by the same limiting dilution method as above. The clone was cultivated in a basal medium RDF containing 1 µg/ml of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG, a mutating agent) for 3 hours in the presence of 5 % CO₂ at 37 °C. The cells were then washed with the same serum-free medium as above and cultivated and adapted in the same serum-free medium as above containing 20 µM of 6-thioguanine and ouabain. The cultivation was carried out in the presence of 5 % CO₂ at 37 °C, and every time subcultivation was repeated, the concentration of ouabain was increased stepwise from 0.1 µM to 0.2, 0.5, 1 and 5 µM. Finally, a monoclone capable of replicating in a serum-free medium containing 20 µM 6-thioguanine and 5 µM ouabain was selected by cloning by the same limiting dilution method as above to give HIH/TOl. EXAMPLE 1 At the time of operation, lymph nodes in the periphery of the cancer tissue were obtained from a patient with liver cancer, and cut to fine pieces by scissors. The lymphocytes inside the lympho nodes were dispersed in RDF medium (composed of a 2:1:1 mixture of RPMI-1640, DME and F-12). The dispersion was then filtered by using a double-layered gauze to remove the fat layer. The cells (lymphocytes >80 %) in the filtrate were collected by a centrifugal method [a human lymphocyte fraction containing human B cell donor (donor B cells)]. The lymphocyte fraction was frozen (-130 °C) in RDF medium containing 20 % of bovine fetal serum and 10 % of dimethyl sulfoxide and stored until the day of cell fusion. 1.0 x 10⁷ donor B cells were cultivated at 37 °C in the presence of 5 % CO₂ in RDF medium containing 5 % human BCGF (B cell growth factor produced by Cellular Products, Inc. and Biotech Research Labs.) and 20 µg/ml goat anti-human IgM (produced by Cappel Company) antibody, and seven days later, centrifuged at 100 G for 15 minutes to collect donor B cells, which were then washed once with RDF medium. Then, the donor lymphocytes (1.0 x 10⁷) and human parent B cells (HIH/TOl) substantially lacking the ability to produce immunoglobulins (1.0 x 10⁷) were mixed and fused in the presence of 50 % polyethylene glycol 1500. The product was centrifuged at 30 G for 15 minutes to remove polyethylene glycol, and freshly, RDF medium containing 10 % bovine fetal serum and hypoxanthine, amethopterin, thymidine and ouabain (HATO) were added. The culture fluid containing these cells was injected into a 96-well microtiter plate at a rate of 200 micro-liters (containing 1.5 x 10⁵ cells) per well. Four weeks later, the plate was incubated in an incubator at 37 °C in the presence of 5 % CO₂. During this time, the RDF medium containing HATO and 10 % bovine fetal serum was replaced once in 4 to 5 days. The parent B cells (HIH/TOl) cannot survive in the presence of amethopterin because it lacks hypoxanthine phosphoribosyltransferase. The lymphocytes cannot proliferate and survive for an extended period of time in an ordinary medium, such as RDF containing 10 % bovine fetal serum, and moreover, die in the presence of ouabain. Accordingly, cells which proliferated for an extended period of time in a medium containing HATO were the fused cells of the lymphocytes and the parent B cells. After cultivation for 4 weeks, five hybridomas were obtained. It was determined by a enzyme-labelled antibody method whether these hybridomas produced human immunoglobulins. This method will be described below. An anti-human immunoglobulin antibody (anti-human Ig antibody) (50 µl) was added dropwise to a microtiter plate and maintained at 37 °C for 1 hour to adsorb it on the plate. The plate was washed three times with 10 mM PBS (gelatin buffer) containing 0.3 % gelatin, and then a 5 % solution of bovine serum albumin was added dropwise (200 microliters) to the plate and the plate was maintained at 37 °C for 0.5 hour to adsorb it on the plate. The plate was washed three times with the gelatin buffer to remove the unadsorbed material. Then, an assay solution (culture supernatant) was added dropwise (50 microliters) and reacted at 37 °C for 1 hour. The plate was then washed three times with the gelatin buffer. Peroxidase-conjugated anti-human Ig antibody (50 microliters) was added dropwise and reacted at 37 °C for 30 minutes to bind it to the human Ig in the culture supernatant (enzyme-labelled antibody technique). The plate was washed three times with the gelatin buffer, and a substrate solution containing hydrogen peroxide and o-phenylenediamine was added and reacted for 10 minutes in a dark chamber. 5N H₂SO₄ (50 microliters) was added to stop the reaction. When the peroxidase-conjugated goat anti-human Ig antibody remained on the microtiter plate, namely when the human Ig bound to it remained, a yellow substrate reaction product having an absorption at 490 nm was produced. The amount of the product was measured by using an absorbance meter to determine the amount of the human Ig contained in the supernatant of the hybridoma culture. When no human Ig existed in the supernatant of the hybridoma culture, the peroxidase-conjugated goat anti-human Ig antibody was washed away in the washing step. By using the above measurement method, it was determined that three out of five hybridoma clones produced antibodies. The clone which produced human IgA was named TOH/B9, and the clone which produced human IgG was named TOH/D5. Four weeks later, each of the hybridomas was inoculated in a 24-well microtiter plate at a rate of 2 ml per well, and the cultivation was continued further for one week. The supernatant of the culture was collected, and the specificity of the Ig produced from the human hybridoma to various cell lines or cancer tissues was examined (Ig having a fixed character or Ig having a specific character). The method will be described below. Various cell lines (available from ATCC) were each cultivated in a medium prepared by adding 10 % bovine fetal serum to DF medium (DME:F-12=1:1). When the number of the cells reached 5 x 10⁶ to 1 x 10⁷, the cells were removed from the bottom of the Petri dish using trypsin, and by centrifugation, the cells were collected and well washed with the culture medium. A fixed number (10⁵/100 microliters) of the cells was injected into each well of a 96-well microtiter plate and maintained overnight at 37 °C to adsorb them on the plate. Then, a 3 % solution of glutaraldehyde (50 microliters) was added dropwise and maintained at 37 °C for 20 minutes to fix the cells. The cells were dropped off by a centrifugal method (200 G, 10 minutes), and the plate was washed with a gelatin buffer three times. A 1 % solution of bovine serum albumin (200 microliters) was added dropwise and maintained at 37 °C for 1 hour to adsorb it on the plate. The plate was washed three times with a gelatin buffer to remove the unadsorbed material. Then, an assay solution (the culture supernatant) was added dropwise in an amount of 50 microliters on the cells and reacted at 37 °C for 1 hour. The plate was washed with a gelatin buffer three times, and subsequently, 50 microliters of peroxidase-conjugated anti-human Ig antibody was added dropwise and reacted at 37 °C for 30 minutes. The plate was washed with a gelatin buffer three times. The amount of human Ig in the culture fluid which bound to the cells was measured by the method described hereinabove with regard to the enzyme-labelled antibody technique, and its specificity to the cell lines was examined. Furthemore, a slice of the cancer tissue fixed with formalin and then embedded in paraffin was treated with an ethanol solution to remove the paraffin, and an assay solution (the culture supernatant) was added, and the specificity of Ig produced by the hybridoma was examined by using a commercial kit "Vectastain ABC kit" made by Vector Laboratories Ltd. It was consequently found that IgA produced by TOH/B9 had a power of binding to cell line PLC/PRF/5 (ATCC CRL 8024) derived from human liver cancer. IgG produced by TOH/D5 was found to have a power of binding to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue. This shows that since the donor B cells were taken from a patient having liver cancer, the clone of the hybridoma produced by cell fusion and having self-replicability produces a monoclonal antibody having the same character as the donor B cell and a specific antigen binding site. Furthermore, to determine that the cells obtained by cell fusion are hybridomas, the DNA content of the cells was examined by the following method. The cell culture was put in a centrifugal tube, and by centrifugal treatment, the supernatant was removed. The cells was then fixed with a 70 % ethanol solution at 4 °C for more than 30 minutes. The supernatant was removed by centrifugal treatment, and a solution of RNase was added. The mixture was gently shaken to decompose RNA. After reaction at 37 °C for 30 minutes, the reaction mixture was washed twice with distilled water. Pripidium iodide (PI) was added, and the cells were stained with it at room temperature for 20 minutes. They were washed with distilled water twice, and diluted with distilled water. Analysis by a cell sorter showed that in both TOH/D5 and TOH/B9, the DNA content was about twice that of the parent human B cells (HIH/TOl). Thus, these cells were determined to be hybridomas. Three weeks later, HATO was removed from the culture media of the hybridomas and the hybridoma were cultivated in a medium composed of RDF and 10 % bovine fetal serum. When 1.0 x 10⁶ cells grew on the media, TOH/B9 produced about 1.3 micrograms/ml of human IgA, and TOH/D5 produced about 0.15 microgram/ml of IgG.

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, NL, SE An antigen-specific human immunoglobulin which is obtainable from human/human hybridoma TOH/B9 (FERM BP-1883) and which has the following biochemical properties: (a) it is a human immunoglobulin A (IgA), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) derived from human liver cancer. An antigen-specific human immunoglobulin which is obtainable from human/human hybridoma TOH/D5 (FERM BP-1882) and which has the following biochemical properties: (a) it is a human immunoglobulin G (IgG), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue. Human/human hybridoma TOH/B9 (FERM BP-1883) which produces antigen-specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. Human/human hybridoma TOH/D5 (FERM BP-1882) which produces antigen specific human immunoglobulin, said hybridoma being a human/human fused cell strain derived from a human B cell taken from a human patient with liver cancer and a subclone of a human lymphoblast cell strain. A human/human hybridoma according to claim 3 which has the following cytobiochemical properties (1) to (5): (1) it secretes (produces) a human immunoglobulin A (IgA), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgA mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) (derived from human liver cancer), and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. A human/human hybridoma according to claim 4 which has the following cytobiochemical properties (1) to (5): (1) it secretes (produces) a human immunoglobulin G (IgG), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgG mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue, and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. An antigen-specific human immunoglobulin according to claim 1 or 2 which is bound to a chemotherapeutic agent, interferon, a high molecular weight toxin, an anti-cancer drug-containing liposome, or a radioactive x-ray sensitive agent. A method of producing an antigen-specific human immunoglobulin, which comprises culturing a hybridoma as claimed in any one of claims 3 to 6 in a culture medium, and recovering the antigen-specific immunoglobulin from the culture broth. A method of producing a hybridoma as claimed in any one of claims 3 to 6, which comprises culturing a human B cell taken from a human patient with liver cancer in the presence of a human B cell growth factor and an anti-human IgM antibody, and fusing the B cell with a subclone of a human lymphoblast cell strain. Claims for the following Contracting State : ES A method for producing human/human hybridoma TOH/B9 (FERM BP-1883), which method comprises culturing a human B cell taken from a human patient with liver cancer in the presence of a human B cell growth factor and an anti-human IgM antibody, and fusing the B cell with a subclone of a human lymphoblast cell strain. A method for producing human/human hybridoma TOH/D5 (FERM BP-1882), which method comprising culturing a human B cell taken from a human patient with liver cancer in the presence of a human B cell growth factor and an anti-human IgM antibody, and fusing the B cell with a subclone of a human lymphoblast cell strain. A method according to claim 1 wherein the hybridoma has the following cytobiochemical properties (1) to (5): (1) it secretes (produces) a human immunoglobulin A (IgA), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgA mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) (derived from human liver cancer), and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. A method according to claim 2 wherein the hybridoma has the following cytobiochemical properties (1) to (5): (1) it secretes (produces) a human immunoglobulin G (IgG), (2) it has a doubling time of about 37 hours, (3) it has a DNA content about twice as large as that of a normal human lymphocyte, (4) the IgG mentioned in (1) above shows bindability to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue, and (5) it can be divided and proliferated in a medium containing hypoxanthine, amethopterin, thymidine and ouabain. A method for producing an antigen-specific human immunoglobulin having the following biochemical properties: (a) it is a human immunoglobulin A (IgA), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) derived from human liver cancer, which method comprises culturing a hybridoma as defined in claim 1 or 3 in a culture medium, and recovering the immunoglobulin from the culture broth. A method for producing an antigen-specific human immunoglobulin having the following biochemical properties: (a) it is a human immunoglobulin G (IgG), and (b) it is capable of binding to human cell line PLC/PRF/5 (Alexander cells) or a human liver cancer tissue, which method comprises culturing a hybridoma as defined in claim 2 or 4 in a culture medium, and recovering the immunoglobulin from the culture broth.

Inventors: HAGIWARA HIDEAKI, NAGAO JUNZO, HAGIWARA, HIDEAKI, NAGAO, JUNZO
Applicants: HAGIWARA HIDEAKI, HAGIWARA YOSHIHIDE, HAGIWARA, HIDEAKI, HAGIWARA, YOSHIHIDE
Application year: 1988
Main classification: C07K15
IPC codes: C07K16, C12N5, C12P21, C07K14, A61K39, C12N15, A61P35, C12R1